Genome-wide expression profiling studies consistently demonstrated an elevated transcriptional output of the MEK/ERK pathway through disabled feedback inhibition in HCL and other BRAF-mutated malignancies, including dysregulation of the DUSP family (i.e., DUSP6) [18,32]. This evidence concerns the gene BRAF and hairy cell leukemia.